Assessments

All participants underwent comprehensive multidisciplinary assessment

  • CLINICALMORE +

    Diagnosis & CDR(CERAD-K)
    Clinical consensus conference
    Medical/Neurological/Psychiatrical comorbidities
    Vascular risk evaluation
    Bodily measurements(e.g. ABI)
  • NEUROIMAGINGMORE +

    11C-PiB-PET-MR
    18F-FDG-PET-MR
    Structural MRI : T1, FLAIR, DTI, SWI
    Functional MRI : rsfMRI, ASL
    MR Angiography
  • QUESTIONNAIRESMORE +

    Subjective cognitive decline
    Depression, anxiety
    Lifetime experience
    - cognitive & physical activity, diet, etc
    Personality traits, stress, and social support
  • NEUROPSYCHILOGICALMORE +

    CERAD-K Neuropsychological battery & Stroop test
    Logical Memory, RCFT, COWAT, Digit span, Korean Adult Reading Test(KART)
  • BLOOD SPECIMENMORE +

    Overnight fasting blood sampling
    Basic blood laboratory test
    APOE genotyping
    Plasma, Serum, DNA, RNA repository for blood-based biomarker & genetic analyses
  • SLEEP & CIRCADIANMORE +

    Sleep-related questionnaires
    - Current & past subjective sleep habit & quality
    - Comorbid sleep disorder
    Wrist actigraphy(for 7 days)

In the first stage, we follow up participants annually for four years. The assessment schedule for each subject is shown in Table. Of the 650 individuals, 210 will be selected to be enrolled for an additional tau-PET (AV1451 PET) imaging protocol.

table image